Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286295059> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W4286295059 endingPage "2503" @default.
- W4286295059 startingPage "2503" @default.
- W4286295059 abstract "2503 Background: Modakafusp alfa (TAK-573) is a first-in-class immune-targeting attenuated cytokine designed to deliver attenuated interferon alpha-2b (IFNα2b) moieties to CD38-expressing cells. It consists of two attenuated IFNα2b molecules genetically fused to the Fc portion of a humanized, anti-CD38, IgG4 monoclonal antibody. Specificity for CD38 and reduced IFN receptor binding affinity of the attenuated IFNα2b molecules significantly reduces the potential for off-target binding and toxicity. Modakafusp alfa has demonstrated immune cell activation and antitumor activities in preclinical mouse models, including tumor models that do not express CD38, and has shown strong clinical responses and immune activation in pts with refractory/relapsed multiple myeloma. The dose-escalation phase of this phase 1b/2 study (NCT04157517) investigated safety, pharmacokinetics, immunogenicity, pharmacodynamics (PD), and preliminary efficacy of modakafusp alfa in metastatic solid tumors. Methods: Adult pts with advanced/metastatic solid tumors received modakafusp alfa IV on day 1 of a 21-day cycle (Q3W). Dose escalation started at 0.1 mg/kg and proceeded based on cycle 1 safety data via a Bayesian model with overdose control principles. Results: Twenty-one pts were dosed in the escalation phase at 0.1 (n = 3), 0.2 (n = 3), 0.4 (n = 3), 0.75 (n = 3), 1.0 (n = 3), and 1.5 mg/kg (n = 6) Q3W; median age 63 y (range 42–80); male 57.1%; GI malignancies 71.4%; median prior lines of therapy 3 (range 2–7). Two pts had dose-limiting toxicities in cycle 1 at 1.5 mg/kg; 1 pt with baseline bone infiltration had grade 4 thrombocytopenia and 1 pt had grade 3 confusion. As of Nov 2021, across all doses, pts received a median of 2 treatment cycles (range 1–11). Modakafusp alfa treatment-related adverse events (TRAEs) reported in 81% of pts included infusion-related reactions (52.4%), chills (47.6%), and nausea (33.3%). Grade ≥3 TRAEs reported in 42.9% of pts included neutropenia (14.3%) and hypertension (9.5%). There was a greater than dose proportional exposure increase in the dose range 0.1–1.5 mg/kg, with no exposure accumulation after Q3W dosing. Incidence rate of post-treatment anti-drug antibody (ADA) was 100%. PD data suggested saturation of peak IFN pathway modulation at ≥0.2 mg/kg in the peripheral blood with duration of modulation increasing with dose. Among the 14 response-evaluable pts, 7 had best response of stable disease, including 1 with cutaneous melanoma who had 21% target lesion reduction. Conclusions: Modakafusp alfa had a manageable safety profile in the dose range 0.1–1.5 mg/kg in pts with solid tumors. Proof of mechanism was validated. The recommended phase 2 dose was determined as 1.0 mg/kg Q3W based on assessment of holistic data and will be tested in combination with a checkpoint inhibitor in selected tumor types. Characterization of ADA and its impact is ongoing. Clinical trial information: NCT04157517." @default.
- W4286295059 created "2022-07-21" @default.
- W4286295059 creator A5001458693 @default.
- W4286295059 creator A5005836117 @default.
- W4286295059 creator A5009512812 @default.
- W4286295059 creator A5009937027 @default.
- W4286295059 creator A5015775019 @default.
- W4286295059 creator A5026638826 @default.
- W4286295059 creator A5039066645 @default.
- W4286295059 creator A5048687593 @default.
- W4286295059 creator A5049294543 @default.
- W4286295059 creator A5063897579 @default.
- W4286295059 creator A5089991821 @default.
- W4286295059 date "2022-06-01" @default.
- W4286295059 modified "2023-09-27" @default.
- W4286295059 title "Dose escalation of a phase 1b/2 study of modakafusp alfa, an immune-targeting attenuated cytokine, in patients (pts) with metastatic solid tumors." @default.
- W4286295059 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.2503" @default.
- W4286295059 hasPublicationYear "2022" @default.
- W4286295059 type Work @default.
- W4286295059 citedByCount "0" @default.
- W4286295059 crossrefType "journal-article" @default.
- W4286295059 hasAuthorship W4286295059A5001458693 @default.
- W4286295059 hasAuthorship W4286295059A5005836117 @default.
- W4286295059 hasAuthorship W4286295059A5009512812 @default.
- W4286295059 hasAuthorship W4286295059A5009937027 @default.
- W4286295059 hasAuthorship W4286295059A5015775019 @default.
- W4286295059 hasAuthorship W4286295059A5026638826 @default.
- W4286295059 hasAuthorship W4286295059A5039066645 @default.
- W4286295059 hasAuthorship W4286295059A5048687593 @default.
- W4286295059 hasAuthorship W4286295059A5049294543 @default.
- W4286295059 hasAuthorship W4286295059A5063897579 @default.
- W4286295059 hasAuthorship W4286295059A5089991821 @default.
- W4286295059 hasConcept C111113717 @default.
- W4286295059 hasConcept C112705442 @default.
- W4286295059 hasConcept C126322002 @default.
- W4286295059 hasConcept C159654299 @default.
- W4286295059 hasConcept C203014093 @default.
- W4286295059 hasConcept C2776146153 @default.
- W4286295059 hasConcept C2777701055 @default.
- W4286295059 hasConcept C2778690821 @default.
- W4286295059 hasConcept C2780868878 @default.
- W4286295059 hasConcept C502942594 @default.
- W4286295059 hasConcept C542903549 @default.
- W4286295059 hasConcept C71924100 @default.
- W4286295059 hasConcept C8891405 @default.
- W4286295059 hasConcept C98274493 @default.
- W4286295059 hasConceptScore W4286295059C111113717 @default.
- W4286295059 hasConceptScore W4286295059C112705442 @default.
- W4286295059 hasConceptScore W4286295059C126322002 @default.
- W4286295059 hasConceptScore W4286295059C159654299 @default.
- W4286295059 hasConceptScore W4286295059C203014093 @default.
- W4286295059 hasConceptScore W4286295059C2776146153 @default.
- W4286295059 hasConceptScore W4286295059C2777701055 @default.
- W4286295059 hasConceptScore W4286295059C2778690821 @default.
- W4286295059 hasConceptScore W4286295059C2780868878 @default.
- W4286295059 hasConceptScore W4286295059C502942594 @default.
- W4286295059 hasConceptScore W4286295059C542903549 @default.
- W4286295059 hasConceptScore W4286295059C71924100 @default.
- W4286295059 hasConceptScore W4286295059C8891405 @default.
- W4286295059 hasConceptScore W4286295059C98274493 @default.
- W4286295059 hasIssue "16_suppl" @default.
- W4286295059 hasLocation W42862950591 @default.
- W4286295059 hasOpenAccess W4286295059 @default.
- W4286295059 hasPrimaryLocation W42862950591 @default.
- W4286295059 hasRelatedWork W1591820460 @default.
- W4286295059 hasRelatedWork W1899411185 @default.
- W4286295059 hasRelatedWork W1934038313 @default.
- W4286295059 hasRelatedWork W195682249 @default.
- W4286295059 hasRelatedWork W2122584026 @default.
- W4286295059 hasRelatedWork W2140167069 @default.
- W4286295059 hasRelatedWork W2411114470 @default.
- W4286295059 hasRelatedWork W2419379701 @default.
- W4286295059 hasRelatedWork W2992709639 @default.
- W4286295059 hasRelatedWork W4298901412 @default.
- W4286295059 hasVolume "40" @default.
- W4286295059 isParatext "false" @default.
- W4286295059 isRetracted "false" @default.
- W4286295059 workType "article" @default.